Our model adapting the CKD-PC risk score accurately predicts the kidney protection benefit of SGLT2 inhibitors in individuals with type 2 diabetes, and no CKD or early-stage CKD (preserved eGFR and normal uACR or low-level albuminuria), who represent approximately 75% of those with type 2 diabetes. Here, SLC5A2 is linked to chronic kidney disease.